Market closedNon-fractional
Alto Neuroscience/ANRO
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About Alto Neuroscience
Alto Neuroscience Inc is a clinical-stage biopharmaceutical company with a mission to redefine psychiatry by leveraging individuals' neurobiology to develop personalized and effective treatment options. The company currently consists of different clinical-stage assets such as ALTO-100, ALTO-202, ALTO-101, and ALTO-300 among others initially targeting depressive disorders and schizophrenia populations as identified by independent brain-based biomarkers.
Ticker
ANRO
Sector
Healthcare
Trading on
NYSE
Industry
Pharmaceuticals
Headquarters
Los Altos, United States
Employees
67
Website
www.altoneuroscience.com
ANRO Metrics
BasicAdvanced
$314M
Market cap
-
P/E ratio
-$5.89
EPS
-
Beta
-
Dividend rate
Price and volume
Market cap
$314M
Financial strength
Current ratio
26.019
Quick ratio
25.718
Long term debt to equity
4.563
Total debt to equity
5.185
Interest coverage (TTM)
-32.32%
Management effectiveness
Valuation
Price to book
1.62
Price to tangible book (TTM)
1.62
Price to free cash flow (TTM)
-2.238
Growth
What the Analysts think about ANRO
Analyst Ratings
Majority rating from 5 analysts.
ANRO Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$0
NaN%
Net income
-$13M
19.64%
Profit margin
0.00%
NaN%
ANRO Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Actual
-$7.77
-$0.76
-
Expected
-$1.67
-$0.46
-$0.67
Surprise
364.16%
64.50%
-
ANRO News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Alto Neuroscience stock?
Alto Neuroscience (ANRO) has a market cap of $314M as of July 06, 2024.
What is the P/E ratio for Alto Neuroscience stock?
The price to earnings (P/E) ratio for Alto Neuroscience (ANRO) stock is 0 as of July 06, 2024.
Does Alto Neuroscience stock pay dividends?
No, Alto Neuroscience (ANRO) stock does not pay dividends to its shareholders as of July 06, 2024.
When is the next Alto Neuroscience dividend payment date?
Alto Neuroscience (ANRO) stock does not pay dividends to its shareholders.
What is the beta indicator for Alto Neuroscience?
Alto Neuroscience (ANRO) does not currently have a Beta indicator.
Buy or sell Alto Neuroscience stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.